Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Advanced Solid Tumors × cemiplimab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 44 Melanoma 19 Squamous Cell Carcinoma of Head and Neck 15 Neoplasms 15 Neoplasm Metastasis 15 Skin Neoplasms 11 Lung Neoplasms 10 Recurrence 8 Head and Neck Neoplasms 8 Carcinoma, Squamous Cell 8 Carcinoma, Renal Cell 8 Colorectal Neoplasms 7 Urinary Bladder Neoplasms 6 Ovarian Neoplasms 6 Breast Neoplasms 6 Adenocarcinoma 6 Triple Negative Breast Neoplasms 5 Prostatic Neoplasms 5 Carcinoma, Merkel Cell 5 Carcinoma, Basal Cell 5 Carcinoma 5 Pancreatic Neoplasms 4 Multiple Myeloma 4 Glioblastoma 4 Colonic Neoplasms 4 Uterine Cervical Neoplasms 3 Stomach Neoplasms 3 Mycosis Fungoides 3 Fallopian Tube Neoplasms 3 Endometrial Neoplasms 3

Interventions

Injections 21 Carboplatin 16 Docetaxel 13 Paclitaxel 10 Bevacizumab 10 pembrolizumab 9 Fluorouracil 7 Cisplatin 7 durvalumab 6 Nivolumab 6 Leucovorin 6 trifluridine tipiracil drug combination 5 tislelizumab 5 linifanib 5 Pemetrexed 5 talazoparib 4 olaparib 4 Panobinostat 4 Oxaliplatin 4 Itraconazole 4 Irinotecan 4 Capecitabine 4 zimberelimab 3 toripalimab 3 sintilimab 3 fludarabine 3 depatuxizumab 3 atezolizumab 3 Sorafenib 3 ST 1481 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04626635 2026-02-02

COMBINE-EGFR-1

Regeneron Pharmaceuticals

Phase 1/2 Recruiting

Other solid neoplasm

Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡